Technology & Software Global On demand · 24-48h

Global Oncolytic Virus Service Market Strategic Research Report

Name: Global Oncolytic Virus Service Market Strategic Research Report
Brand: Market Research Reports, Inc.
Price: 3500 USD
Availability: PreOrder

Global Oncolytic Virus Service Market Strategic Research Rep…

$3,500 USD

Strategic Research Report

Global Oncolytic Virus Service Market

$87.45B2025

21.6%CAGR

2032Forecast

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Measles Virus (MeV), Herpes Simplex Virus (HSV-1), Others

By Application: Tumor Treatment, Scientific Research

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Creative Biolabs, Creative Biogene, Recipharm, Nabios, IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza, ABL, Takara Bio, Libentech

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2025 · forecast to 2032

Length: 105 pages

Market size 2025

$87.45B

Billion USD

Forecast CAGR

21.6%

2025-2032

Forecast 2032

$343.8B

Projected

Regiones

Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Oncolytic Virus Service market size is predicted to grow from US$ 87,450 million in 2025 to US$ 335,280 million in 2032; it is expected to grow at a CAGR of 21.6% from 2026 to 2032.

The main contents of oncolytic virus services include virus screening, virus production, quality testing, drug efficacy evaluation, etc. In this process, pharmaceutical companies can select different virus strains and, after appropriate genetic engineering, be used to treat different types of tumors.

With the continuous development of gene editing technology and viral vector technology, more new oncolytic viruses will be developed, providing more options for tumor treatment.

This report presents a comprehensive overview of the global Oncolytic Virus Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Measles Virus (MeV)
Herpes Simplex Virus (HSV-1)
Others

Segment by Application

Tumor Treatment
Scientific Research

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Oncolytic Virus Service market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Tumor Treatment, Scientific Research evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Oncolytic Virus Service Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports

Market size CAGR 21.6%

Regional growth momentum

Market share by segment

Key metrics

Base value

$87.45B

2025

Forecast

$343.8B

2032

CAGR

21.6%

2025–2032

Regiones

global

Key companies

Creative BiolabsCreative BiogeneRecipharmNabiosIDT BiologikaFUJIFILM Diosynth BiotechnologiesExotheraLonza

Segments covered in this report

By Type

Measles Virus (MeV)Herpes Simplex Virus (HSV-1)Others

By Application

Tumor TreatmentScientific Research

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 Measles Virus (MeV)
3.1.3 Herpes Simplex Virus (HSV-1)
3.1.4 Others
3.1.5 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Tumor Treatment
4.1.3 Scientific Research
4.1.4 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 China
6.1.2 Japan
6.1.3 Korea
6.1.4 Southeast Asia
6.1.5 India
6.1.6 Australia
6.1.7 Rest of Asia Pacific
6.2 North America
6.2.1 United States
6.2.2 Canada
6.2.3 Mexico
6.2.4 Rest of North America
6.3 Europe
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Russia
6.3.6 Rest of Europe
6.4 Middle East & Africa
6.4.1 Egypt
6.4.2 South Africa
6.4.3 Israel
6.4.4 Turkey
6.4.5 GCC Countries
6.4.6 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Brazil
6.5.2 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 Creative Biolabs
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 Creative Biogene
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 Recipharm
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 Nabios
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 IDT Biologika
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 FUJIFILM Diosynth Biotechnologies
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 Exothera
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 Lonza
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 ABL
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 Takara Bio
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)
8.11 Libentech
8.11.1 Company Overview
8.11.2 Key Products & Segments
8.11.3 Financial Performance (2023–2025)
8.11.4 Business Strategy
8.11.5 SWOT Analysis
8.11.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Oncolytic Virus Service market size?

The global Oncolytic Virus Service market is estimated at US$ 87.45 billion in 2025 (base year) and is projected to reach US$ 335.28 billion by 2032.

What growth rate is expected for the Oncolytic Virus Service market through 2032?

The market is expected to grow at a CAGR of 21.6% from 2026 to 2032, expanding from US$ 87.45 billion in 2025 to US$ 335.28 billion in 2032, roughly 3.8 times its base-year value.

How is Oncolytic Virus Service defined?

How is the Oncolytic Virus Service market segmented by type?

By type, the market is segmented into Measles Virus (MeV), Herpes Simplex Virus (HSV-1) and Others.

What are the key applications of Oncolytic Virus Service?

Key applications covered include Tumor Treatment and Scientific Research.

Which companies are profiled in the Oncolytic Virus Service market report?

Key players profiled include Creative Biolabs, Creative Biogene, Recipharm, Nabios, IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera and Lonza, among 11 companies covered in total.

What geographies does the Oncolytic Virus Service market analysis include?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

Who should buy the Oncolytic Virus Service market report?

The report is intended for manufacturers and solution providers, distributors and end users in Tumor Treatment and Scientific Research, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Oncolytic Virus Service market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.